Tina Davis
YOU?
Author Swipe
View article: Interpreting Convolutional Neural Network Activation Maps with Hand-crafted Radiomics Features on Progression of Pediatric Craniopharyngioma after Irradiation Therapy
Interpreting Convolutional Neural Network Activation Maps with Hand-crafted Radiomics Features on Progression of Pediatric Craniopharyngioma after Irradiation Therapy Open
Purpose: Convolutional neural networks (CNNs) are promising in predicting treatment outcome for pediatric craniopharyngioma while the decision mechanisms are difficult to interpret. We compared the activation maps of CNN with hand crafted …
View article: Deep-learning-based Radiomics on Mitigating Post-treatment Obesity for Pediatric Craniopharyngioma Patients after Surgery and Proton Therapy
Deep-learning-based Radiomics on Mitigating Post-treatment Obesity for Pediatric Craniopharyngioma Patients after Surgery and Proton Therapy Open
Purpose: We developed an artificial neural network (ANN) combining radiomics with clinical and dosimetric features to predict the extent of body mass index (BMI) increase after surgery and proton therapy, with advantage of improved accurac…
View article: Data from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Data from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-AL…
View article: Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends. Legends for supplementary tables S1-S3 and supplementary figures S1-S6 which support data in the manuscript, but could not be included due to space constraints.
View article: Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Supplementary Tables S1-S3 and Supplementary Figures S1-S6. Table S1 - EC50 values for B-cell malignancies treated with HDAC inhibitors of varying isoform selectivity Table S2 - EC50 values for B-ALL cell line treated with a panel of HDAC …
View article: Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends. Legends for supplementary tables S1-S3 and supplementary figures S1-S6 which support data in the manuscript, but could not be included due to space constraints.
View article: Data from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Data from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-AL…
View article: Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Supplementary Tables S1-S3 and Supplementary Figures S1-S6. Table S1 - EC50 values for B-cell malignancies treated with HDAC inhibitors of varying isoform selectivity Table S2 - EC50 values for B-ALL cell line treated with a panel of HDAC …
View article: 902 NKX019, an off-the-shelf CD19 CAR-NK cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs
902 NKX019, an off-the-shelf CD19 CAR-NK cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs Open
Background NKX019 is an investigational CD19-targeting chimeric antigen receptor (CAR) natural killer (NK) cell therapy with engineered persistence for treating B cell malignancies. NKX019 exhibits more rapid cytotoxic kinetics than CD19-d…
View article: Artificial Neural Network Modelling Using Pre-Operative MRI Features to Predict Obesity in Pediatric Patients With Craniopharyngioma Treated With Proton Therapy
Artificial Neural Network Modelling Using Pre-Operative MRI Features to Predict Obesity in Pediatric Patients With Craniopharyngioma Treated With Proton Therapy Open
View article: 127 Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell
127 Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell Open
Background Natural killer (NK) cells are highly effective and fast-acting cytolytic cells capable of eradicating target cells with limited adverse effects such as cytokine release syndrome (CRS) or graft-versus-host disease. Chimeric antig…
P159 PHENOTYPIC CHARACTERIZATION OF INFLAMMATORY BOWEL DISEASE BIOPSIES REVEAL THAT MAST CELLS ARE SIGNIFICANTLY ELEVATED AND ACTIVATED IN PATIENTS WITH ULCERATIVE COLITIS Open
View article: Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic
Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic Open
[This corrects the article DOI: 10.1371/journal.pbio.2005924.].
View article: TMIC-15. OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODEL
TMIC-15. OMX IS A TUMOR MICROENVIRONMENT MODIFIER THAT RESTORES ANTI-TUMOR IMMUNITY AND IMPROVES ANTI-TUMOR EFFICACY BY REDUCING TUMOR HYPOXIA IN INTRACRANIAL GLIOBLASTOMA MOUSE MODEL Open
Intratumoral hypoxia is associated with resistance to chemo- and radio-therapies and poor patient outcomes. In addition, hypoxia promotes the immune escape of tumors by altering the recruitment and function of innate and adaptive immune ef…
View article: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic
Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic Open
The heart exhibits the highest basal oxygen (O2) consumption per tissue mass of any organ in the body and is uniquely dependent on aerobic metabolism to sustain contractile function. During acute hypoxic states, the body responds with a co…
View article: IMST-52. OMX, AN IND-STAGE BROAD-ACTING OXYGEN CARRIER, IMMUNOSENSITIZES THE TUMOR MICROENVIRONMENT AND PROMOTES EFFECTOR T CELL RESPONSES IN THE GL261 INTRACRANIAL SYNGENEIC GLIOBLASTOMA MODEL
IMST-52. OMX, AN IND-STAGE BROAD-ACTING OXYGEN CARRIER, IMMUNOSENSITIZES THE TUMOR MICROENVIRONMENT AND PROMOTES EFFECTOR T CELL RESPONSES IN THE GL261 INTRACRANIAL SYNGENEIC GLIOBLASTOMA MODEL Open
Hypoxia, or lack of oxygen, is a hallmark of glioblastoma and is correlated with tumor progression and decreased overall survival. As a key modulator of the tumor microenvironment, hypoxia promotes immunosuppression through activation of m…
View article: ATPS-49RESULTS OF A PHASE 0 CLINICAL TRIAL IN CANINE BRAIN CANCER EVALUATING SAFETY AND ACTIVITY OF OMX-4.80P, A PROTEIN OXYGEN CARRIER IND CANDIDATE FOR TREATMENT OF GLIOBLASTOMA
ATPS-49RESULTS OF A PHASE 0 CLINICAL TRIAL IN CANINE BRAIN CANCER EVALUATING SAFETY AND ACTIVITY OF OMX-4.80P, A PROTEIN OXYGEN CARRIER IND CANDIDATE FOR TREATMENT OF GLIOBLASTOMA Open
BACKGROUND: Hypoxia in solid tumors blunts the tumor cytotoxicity of radiotherapy (RT) and is a major independent predictor of poor patient outcomes in glioblastoma (GB). To increase tumor oxygenation, Omniox has engineered a novel oxygen …
View article: NIMG-45REAL-TIME PET IMAGING DEMONSTRATES TUMOR ACCUMULATION AND OXYGENATION BY OMX-4.80P, AN OXYGEN CARRIER ENGINEERED FOR THE TREATMENT OF GLIOBLASTOMA
NIMG-45REAL-TIME PET IMAGING DEMONSTRATES TUMOR ACCUMULATION AND OXYGENATION BY OMX-4.80P, AN OXYGEN CARRIER ENGINEERED FOR THE TREATMENT OF GLIOBLASTOMA Open
BACKGROUND: Hypoxia is a hallmark of glioblastoma (GB) and is correlated with tumor progression and decreased overall survival. OMX-4.80P is a protein oxygen carrier engineered for the treatment of GB in combination with radiotherapy. Prio…
View article: Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Open
Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may…